WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial-Reference-Cited by-同舟云学术

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

Published:2013 Issue:1 Volume:14 Page:261
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Hofmann Daniel,Nitz Ulrike,Gluz Oleg,Kates Ronald E,Schinkoethe Timo,Staib Peter,Harbeck Nadia

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Reference22 articles.

1. Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review

2. Jenseits von Staging, Typing und Grading

3. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

4. Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial

5. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium;Modern Pathology;2024-07

2. Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial;Therapeutic Advances in Medical Oncology;2024-01

3. Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences;2023-11-13

4. Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report;Surgical Case Reports;2023-06-21

5. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial;Annals of Oncology;2023-06